Citations

Showing 10 of 107895 citations.

The Relationship between Left Epicardial Adipose Tissue Attenuation at CT and Atrial Fibrillation: A Systematic Review and Meta-Analyses
Meulendijks, Eva R. , Zappala, Pietro , Vries, Tim A.C. de , Terpstra, M M , Telders, Carolina Janssen, Krul, Sébastien P.J., Planken, R. Nils , de Vries, Tim A C , Terpstra, Marc M , de Groot, Joris R , Planken, R Nils , Janssen-Telders, Carolina

Mayo Clinic

Radiology: Cardiothoracic Imaging | December 18, 2025 | Volume: 7 | Issue: 6 | Pages: No page available

10.1148/ryct.250015 | PMID 41410573 Get It

Increased epicardial adipose tissue attenuation on CT images was associated with the presence and recurrence of atrial fibrillation in studies using consistent or corrected tube voltage settings, suggesting its potential as a prognostic marker.
Atrial fibrillation through the lens of precision medicine: what clinicians need to know
Lamata, Pablo, Giudicessi, John R. , Krittanawong, Chayakrit , Namjouyan, Kamran , Lamata, Pablo , Virk, Hafeez Ul Hassan , Glicksberg, Benjamin S.

Mayo Clinic

Future Cardiology | December 18, 2025 | Volume: 22 | Issue: 2 | Pages: 167-180

10.1080/14796678.2025.2603897 | PMID 41410542 Get It

Living liver donor safety: Early postoperative considerations of living liver donation guidelines from the ILTS-iLDLTG consensus conference
Sayed, Blayne Amir, Tejedor, Marta , Kathirvel, Manikandan , Bhangui, Prashant , Ghanekar, Anand, Kasahara, Mureo , Scatton, Olivier, Ghobrial, Mark, Klair, Tarunjeet , Rajakumar, Akila , Bezinover, Dimitri , Bittermann, Therese , Don, C, Luzzi, Carla , Tsien, Cynthia , Egawa, Hiroto , Ascher, Nancy L. , Bröering, Dieter C. , Chen, Chao‐Long , Lerut, Jan , Mas, Valeria R. , Taner, Timuçin , Vyas, Mary, Wiggins, Chantal, Olthoff, Kim M. , Rela, M, Selzner, Nazia, Sayed, Blayne A. , Bhangui, Prashant , Rammohan, Ashwin , Selzner, Nazia , Tejedor, Marta , Sayed, Blayne A , Chadha, Ryan , Ivanics, Tommy , Kim, Dong‐Sik , Scatton, Olivier , Ghobrial, Mark, Sudhindran, S , Benedetto, Fabrizio Di , Burra, Patrizia , Hirschfield, Gideon M. , Terrault, Norah A. , Wiggins, Chantal, Fung, John J. , Heimbach, Julie K. , Selzner, Nazia

Mayo Clinic

Liver Transplantation | December 18, 2025 | Volume: 32 | Issue: 6 | Pages: 913-924

10.1097/lvt.0000000000000791 | PMID 41410428 Get It

Living donor liver transplantation (LDLT) is a life-saving procedure for patients with end-stage liver disease. As its use expands worldwide, ensuring the safety and well-being of live liver donors (LLD) is of paramount importance. Published evidence on early postoperative complications after living donor hepatectomy—those occurring within 90 days of surgery—is limited, and standardized postoperative care protocols are lacking. The International Liver Transplantation Society (ILTS) and the International Living Donor Liver Transplantation Group (iLDLT Group) convened a consensus conference in Toronto in March 2025 to develop guidelines for the safe care of the LLDs. This manuscript details the recommendations on early postoperative considerations for the safety of LLDs developed by Working Group III (WGIII) of the Consensus Scientific Committee, using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system for assessment of recommendations, and the Danish model of consensus. WGIII addressed four key areas: (1) standardized postoperative care, (2) early biliary complications, (3) early postoperative liver dysfunction, and (4) early postdischarge follow-up. This report emphasizes the need for vigilant postoperative monitoring in specialized units, with access to experienced providers and defined clinical pathways. Structured clinical and psychosocial follow-up protocols, perioperative prophylaxis for surgical site infections and venous thromboembolism, and management of early biliary and vascular complications are discussed. These may help standardize care, reduce complications and improve short-term outcomes in LLDs.
Long-term considerations following living liver donation—Guidelines from the 2025 ILTS-iLDLT consensus conference on living liver donor safety
Sayed, Blayne A. , Jung, Dong-Hwan, Watt, Kymberly D. , Maluf, Daniel G. , Zhu, Zhi‐Jun , Eghtesad, Bijan , Minnee, Robert C. , James, Paul M., Man, Nancy Kwan, Liapakis, AnnMarie , Fipps, David C. , Taner, Timuçin , Wiggins, Chantal, Ascher, Nancy L. , Mas, Valeria, Chen, Chao‐Long, Vyas, Mary, Suk-Suh, Kyung, Broering, Dieter , Lerut, Jan , Olthoff, Kim M. , Rela, Mohamed, Fipps, David C , Sayed, Blayne A , Chan, Albert C Y , Rammohan, Ashwin , Shankar, Sadhana , Syn, Nicholas L. X. , Mathew, Johns Shaji , Bhangui, Prashant , Jung, Dong‐Hwan , Pomfret, Elizabeth , Roberts, John P. , Selzner, Markus , Chan, Albert , Chaudhary, Abhideep , Eguchi, Susumu , James, Paul, Goldaracena, Nicolás , Kodali, Sudha , Kim, Jong Man , Wiggins, Chantal, Terrault, Norah A. , Burra, Patrizia , Hirschfield, Gideon M. , Heimbach, Julie K. , Selzner, Nazia , Rela, Mohamed

Mayo Clinic

Liver Transplantation | December 18, 2025 | Volume: 32 | Issue: 8 | Pages: 1194-1209

10.1097/lvt.0000000000000790 | PMID 41410423 Get It

Living liver donation is a critical component for addressing organ shortage and improving outcomes for patients with end-stage liver disease. As the prevalence of living donor liver transplantation (LDLT) increases worldwide, understanding and optimizing long-term donor health is paramount. The 2025 International Liver Transplantation Society and International Living Donor Liver Transplantation Society (ILTS-iLDLT) Consensus Conference convened experts in the field of liver transplantation to establish evidence-based guidelines focused on the long-term medical, psychological, and social considerations following living liver donation. The aim of this working group was to integrate current evidence and expert consensus on donor follow-up protocols, risk assessment, and management strategies to promote long-term donor health, quality of life, and living liver donor programs globally to safeguard the welfare of this unique population.
Tissue regenerative medicine: Clinical advances, challenges, and opportunities
Badawy, Seleem , Gopinath, Varshiny , Espinosa, Ana M. Diaz , Kelmser, Ethan C., Duke, Victoria R. , Kamaraju, Veda , Nakayama, Karina, Manna, Manoj , Liu, Julianne J-Y , Shen, K. Robert , Suthiwanich, Kasinan , Duke, Victoria , Kamaraju, Veda , Manna, Manoj , Liu, Julianne J-Y , Nunes, Sara S , Shen, Keyue , Huang, Ngan F , Diaz Espinosa, Ana M , Badawy, Seleem , Gopinath, Varshiny , Suthiwanich, Kasinan , Kelmser, Ethan C, Nakayama, Karina

Mayo Clinic

APL Bioengineering | December 18, 2025 | Volume: 9 | Issue: 4 | Pages: No page available

10.1063/5.0296897 | PMID 41424914 Get It

Regenerative medicine is transforming how we restore tissue function, leveraging advances in cell and molecular biology, biomaterials, and engineered microenvironments. While there have been notable advances and rapid progress over the past few decades, ongoing challenges persist in the technical development and effective translation of these advancements to clinical care. This perspective highlights clinically promising examples and critically assesses present challenges in translating tissue regenerative medicine therapies from the bench to the clinic. We further examine the evolving landscape of regenerative medicine by describing strategies to optimize the cellular microenvironment, the impact of patient demographics, and the use of artificial intelligence to shape the future of this field.
Molecular and clinical stratification of astroblastomas: Three distinct fusion-defined groups informing risk-adapted treatment strategies
Federico, Aniello , Schmitt-Hoffner, Felix , Fonseca, Adriana , Geisemeyer, Neal, Bruckner, Katharina , Mauermann, Monika, Sill, Martin , Stichel, Damian , Sturm, Dominik , Schüller, Ulrich , Tauziede-Espariat, Arnault, Capper, David, Abdullaev, Zied , Selt, Florian , Williamson, Lane, Miele, Evelina, Snuderl, Matija, Brandner, Sebastian, Lugt, Jasper van der , Bunt, Jens , Kolenova, Alexandra, Wilson, Yelena , Weintraub, Lauren , Spiegl-Kreinecker, Sabine, Aistleitner, Barbara, Zapotocky, Michal, Ramaswamy, Vijay, Korshunov, Andrey, Jones, Barbara C. , Kjaersgaard, Mimi, Kranendonk, Mariëtte E.G. , Haberler, Christine, Packer, R., Jäger, Natalie, Sahm, Prof Felix, Koster, J., Aldape, Kenneth, Hoff, Katja von , Gojo, Johannes , Kool, M., Varlet, Pascale , Capper, David , Selt, Florian , Antonelli, Manila , Brandner, Sebastian , Bunt, Jens , Raghunathan, Aditya , Ramaswamy, Vijay , Haberler, Christine , von Deimling, Andreas , Sahm, Felix , Aldape, Kenneth , Gojo, Johannes , Kool, Marcel , Von Hoff, Katja , Geisemeyer, Neal, Tauziède-Espariat, Arnault , Capper, David , Schrimpf, Daniel , Donson, Andrew M. , Miele, Evelina , Snuderl, Matija , Łastowska, Maria , Kramm, Christof Maria , Kolenová, Alexandra , Raghunathan, Aditya , Hansford, Jordan R. , Spiegl‐Kreinecker, Sabine , Baroni, Lorena , Zápotocký, Michal , Ramaswamy, Vijay , Korshunov, Andrey , Kjærsgaard, Mimi , Haberler, Christine , Deimling, Andreas von , Sahm, Felix , Pfister, Stefan M. , Kool, Marcel

Mayo Clinic

Neuro-Oncology | December 18, 2025 | Volume: 28 | Issue: 4 | Pages: 1005-1019

10.1093/neuonc/noaf283 | PMID 41429568 Get It

Abstract Background Astroblastomas are rare brain tumors predominantly affecting children and young adults, for which molecular subtypes and clinical management remain undefined. Methods We analyzed tumor samples, molecular profiles, and clinical data from 200 patients, classified as “Astroblastoma, MN1-altered” under WHO criteria, using DNA methylation profiling, DNA/RNA profiling/sequencing, and survival analyses. Results DNA methylation analyses identified 3 groups: Group A (n = 143, characterized by MN1::BEND2 fusions, predominantly supratentorial location, with striking female predominance and favorable survival); Group B (n = 37, epigenetically and transcriptionally closely related to Group A, but characterized by EWSR1::BEND2 fusions, with spinal and infratentorial locations and poor prognosis); and Group C (n = 20, epigenetically and transcriptionally distinct, characterized by MN1::CXXC5 fusions, exclusively supratentorially located, with favorable survival). Progression-free and overall survival were significantly shorter in Group B (5-year PFS 14%; 10-year OS 54%) compared to A (5-year PFS 47%; 10-year OS 89%) and C (5-year PFS 75%; 10-year OS 89%). Radiotherapy improved PFS in Group B (hazard ratio 0.25), while no clear benefit was identified for Groups A and C. Conclusions Astroblastoma, MN1-altered, comprises 3 molecularly and clinically distinct groups, characterized by different fusion genes, including those without MN1. These new insights, including the identification of potential predictive biomarkers like 14q/16q loss, provide a framework for the development of risk-stratified therapeutic approaches. Importantly, we identified a molecularly defined high-risk group that benefits from radiation therapy. Our findings redefine Astroblastoma as a molecularly diverse tumor type, propose a refined classification, support the development of risk-adapted therapeutic strategies and provide a rational standard of care.
Evaluation of ePLAR, the echocardiographic pulmonary to left atrial ratio, in a large cohort with pulmonary hypertension
Scalia, Isabel G. , Ali, Nima Baba , Bismee, Nadera N. , Mahmoud, Ahmed K, Esfahani, Sogol Attaripour , Sheashaa, Hesham, Ibrahim, Oman H, Abdelfattah, Fatmaelzahraa , Barry, Timothy, Tamarappoo, Balaji , Scott, Robert L, Rosenthal, Julie , Lester, Steven J, Ayoub, Chadi, Arsanjani, Reza, Mahmoud, Ahmed , Scalia, Isabel G , Pietri, Milagros Pereyra, Awad, Kamal , Javadi, Niloofar , Mahmoud, Ahmed K , Tamarappoo, Balaji K, Alsidawi, Said , Ayoub, Chadi , Farina, Juan M. , Pereyra, Milagros , Abbas, Mohammed Tiseer , Awad, Kamal , Barry, Timothy , Alsidawi, Said , Scott, Robert L. , Lester, Steven J., Arsanjani, Reza

Mayo Clinic

European Heart Journal Open | December 18, 2025 | Volume: 6 | Issue: 3 | Pages: No page available

10.1093/ehjopen/oeaf174 | PMID 42282056 Get It

Abstract Aims Pre-capillary pulmonary hypertension (PHTN), typically due to intrinsic pulmonary pathology, requires right heart catheterization (RHC) for diagnosis. ePLAR, the echocardiographic pulmonary to left atrial ratio [calculated: tricuspid regurgitation maximum velocity (TRVmax) divided by mitral valve E to e′ wave ratio (E/e′)], has been demonstrated as a promising non-invasive surrogate for characterization of pre-capillary PHTN. As such, this study aimed to further evaluate the diagnostic utility of ePLAR in a large cohort of patients with PHTN. Methods and results All RHCs between 2018 and 2023 across three tertiary centres were retrospectively reviewed. Patients with PHTN were characterized as pre-capillary or post-capillary (isolated or combined). Concurrent ePLAR was calculated. ROC analysis evaluated the accuracy of ePLAR in detecting pre-capillary PHTN. Overall, 2235 patients had PHTN by RHC, mean age 63.5 ± 14.7 years, 53.5% male. Of these, 43.3% had pre-capillary PHTN. ROC analysis demonstrated ePLAR to have good accuracy in detection of pre-capillary PHTN (AUC 0.760), with a cutoff of 0.20 m/s demonstrating a sensitivity and specificity of 77% and 60% respectively. This persisted on sensitivity analysis for contemporaneous investigations and for right ventricular function. Conclusion In this large cohort, ePLAR was validated as an accurate tool for identifying patients with pre-capillary PHTN. This widely available, non-invasive, and reproducible parameter can have an important role in the work up of PHTN and may guide the need for invasive testing.
Cortical asymmetry in autosomal dominant Alzheimer’s disease progression
Pérez-Millan, Agnès , Falgàs, Neus , Borrego-Écija, Sergi, Antonell, Anna, Fernández-Villullas, Guadalupe, Esteller-Gauxax, Diana, Tort-Merino, Adrià, Bargalló, Núria, Balasa, Mircea, Lladó, Albert, Chrem, Patricio, Day, Gregory S. , Devenney, Emma , Huey, Edward D. , Ikeuchi, Takeshi, Jucker, Mathias, Roh, Jee Hoon , Vitali, Paolo , Ortíz, Ana Luisa Sosa, Llibre-Guerra, Jorge J, Gordon, Brian A., Sánchez-Valle, Raquel, (DIAN), The Dominantly Inherited Alzheimer Network, Daniels, Alisha , Courtney, Laura, Ziegemeier, Angela, Skrbec, Karina, Hellm, Cortaiga, Martin, Mariana , Ziegemeier, Ellen , Bartzel, Jamie, Xiong, Chengie , Xu, Xiong, Lu, Ruijin, Li, Yan , Nie, Yuzheng , Gremminger, Emily, Perrin, Richard J. , Franklin, Erin , Ibanez, Laura, Jerome, Gina, Stauber, Jennifer, Baker, Bryce, Minton, Matthew, Cruchaga, Carlos C, Goate, Alison M, Renton, Alan E, Picarello, Danielle M. , Benzinger, Tammie L S, Hornbeck, Russ C. , Chen, Allison, Chen, Charles D., Flores, Shaney, Joseph-Mathurin, Nelly, Jackson, Kelley, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Wang, Qing, Sabaredzovic, Edita, Scott, Jalen , Simmons, Ashlee, Rizzo, Jacqueline, Vlassenko, Andrei G. , Wang, Yong, Hassenstab, Jason, Smith, Jennifer, Stout, Sarah, Marsh, Jacob, Morris, John C, Barthélemy, Nicolas R. , Xu, Jinbin , Ikonomović, Snežana, Graff-Radford, Neill R, Farlow, Martin R. , Chhatwal, Jasmeer P. , Maa, Courtney, Ishiguro, Takanobu , Ishii, Kenji, Senda, Michio, Salloway, Stephen , Bechara, Jacob A, Martins, Ralph, Fox, Nick C, Ryan, Natalie S. , Laske, Christoph , Timofejavaite, Reda, Kuder-Buletta, Elke, Graber-Sultan, Susanne, Obermueller, Ulrike, Xiong, Chengjie , Rödenbeck, Yvonne, Vӧglein, Jonathan, Méndez, Patricio Chrem, Vazquez, Silvia, Leon, Yudy Milena, Ramirez, Laura, Baena, Ana , Bocanegra, Yamile , Levey, Allan, Johnson, Erik C B, Seyfried, Nicholas T. , Ringman, John M. , Fagan, Anne M. , Mori, Hiroshi, Lopera, Francisco , Goate, Alison , Hassenstab, Jason , Borrego‐Écija, Sergi , Pérez‐Millan, Agnès , Ikeuchi, T , Vöglein, Jonathan , Roh, Jee Hoon , Vitali, Paolo , Gordon, Brian A , Bateman, Randall J , Sánchez-Valle, Raquel , Day, Gregory S , Xiong, Chengjie , Hassenstab, Jason , Borrego-Écija, Sergi , Goate, Alison M , Bosch, Beatríz , Antonell, Anna, Fernández‐Villullas, Guadalupe , Esteller, Diana , Tort‐Merino, Adrià , Balasa, Mircea , Lladó, Albert , Aguillon, David , Ikeuchi, Takeshi , Jucker, Mathias , Kasuga, Kensaku , Vöglein, Jonathan , Llibre‐Guerra, Jorge J. , Gordon, Brian A. , McDade, Eric , Bateman, Randall J. , Sánchez‐Valle, Raquel , Supnet, Charlene , Lu, Ruijin, Wang, Guoqiao , Ibanez, Laura , Cruchaga, Carlos , Fulton‐Howard, Brian , Banks, Jessica N , Flores, Shaney , Goyal, Manu S. , Hobbs, Diana A. , Joseph‐Mathurin, Nelly , McCullough, Austin , McKay, Nicole S. , Wang, Yong , Smith, Jennifer, Stout, Sarah H., Aschenbrenner, Andrew J. , Karch, Celeste M. , Marsh, Jacob A. , Holtzman, David M. , Berman, Sarah , Graff‐Radford, Neill R. , Senda, Michio , Niimi, Yoshiki , Schofield, Peter R. , Brooks, William S. , Bechara, Jacob , Cash, David M. , Laske, Christoph , Fougère, Christian la , Reischl, Gerald , Lee, Jae Hong , Allegri, Ricardo , Surace, Ezequiel , Vazquez, Silvia, Ramírez, Laura, Serna, Laura, Johnson, Erik C. B. , Masters, Colin L. , Noble, James M. , Lopera, Francisco Javier

Mayo Clinic

Brain Communications | December 18, 2025 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcaf488 | PMID 41523185 Get It

Abstract The cortical asymmetry index evaluates the cortical thickness asymmetry between hemispheres. We investigated cortical asymmetry index in asymptomatic and symptomatic mutation carriers of autosomal dominant Alzheimer’s disease to explore the brain asymmetry within the Alzheimer’s disease continuum. Sixty baseline T1-weighted MRI scans were obtained from the Clinic Barcelona cohort. Baseline and longitudinal MRI data from 564 participants within the dominantly inherited Alzheimer network observational study were used as an independent, confirmatory cohort. Cerebrospinal fluid and plasma neurofilament light chain levels were included when available. Cortical thickness was calculated using Freesurfer and cortical asymmetry index was calculated via an open-source pipeline. Cross-sectional analyses examined cortical asymmetry index differences based on clinical classification and APOE ε4 status, adjusting for age, sex and estimated years from onset, while correlations were assessed with age, estimated years from onset, mini-mental state examination scores, and neurofilament light. Longitudinal cortical asymmetry index evolution was modelled using generalized additive models in the dominantly inherited Alzheimer network observational study cohort, incorporating age, sex, and the interaction between group and estimated years from onset. The cortical asymmetry index successfully distinguished asymptomatic mutation carrier and symptomatic mutation carriers from healthy controls in the Clinic Barcelona cohort and symptomatic mutation carriers from controls in dominantly inherited Alzheimer network observational study. Higher cortical asymmetry index in mutation carriers (asymptomatic mutation carrier and symptomatic mutation carriers combined) and in symptomatic mutation carriers were associated with higher plasma neurofilament light levels, a closer proximity to symptom onset, and lower mini-mental state examination in the Clinic Barcelona cohort. In the dominantly inherited Alzheimer network observational study cohort, mutation carriers exhibited increased cortical asymmetry index compared to controls and correlated with elevated neurofilament light (plasma and Cerebrospinal fluid), lower mini-mental state examination, and a closer proximity to symptom onset. APOE3/3 carriers showed greater asymmetry than other APOE genotypes and significant cortical asymmetry index differences between asymptomatic mutation carrier and symptomatic mutation carriers. Longitudinally, cortical asymmetry index increased over time significantly in symptomatic mutation carriers. These findings underscore brain asymmetry as a potential biomarker for early Alzheimer’s disease progression in autosomal dominant Alzheimer’s disease, with implications for detection and monitoring tracking disease-related neuroanatomical changes.
Pakistan’s rising cardiovascular disease burden associated with modifiable risk factors: an urgent appeal for evidence-driven action
Mubashir, Eshaal, Cheema, Asad Ali Ahmed , Noshab, Muhammad, Cheema, Asad Ali Ahmed , Noshab, Muhammad , Siddiqi, Ahmed Kamal , Mubashir, Eshaal, Naeem, Mohammad

Mayo Clinic

Annals of Medicine & Surgery | December 18, 2025 | Volume: 88 | Issue: 1 | Pages: 59-60

10.1097/ms9.0000000000004565 | PMID 41496917 Get It

Identifying global trends from case reports of fibrodysplasia ossificans progressiva: a scoping review
Scott, Christiaan, Mukaddam, Mona Al, Davis, Michelle, Cunto, Carmen L. De, Hsiao, Edward C. , Pignolo, Robert J., Schwegler, Odette , Artyomenko, Alexander, Croskery, Kim, Hanman, Kate, Sanchot, Boris, Warnants, Emma , Kaplan, Frederick S., Scott, Christiaan , Hsiao, Edward C , Scott, Christiaan, Mukaddam, Mona Al, Davis, Michelle, Cunto, Carmen L. De, Pignolo, Robert J., Schwegler, Odette , Artyomenko, Alexander, Croskery, Kim, Hanman, Kate, Sanchot, Boris, Warnants, Emma , Kaplan, Frederick S.

Mayo Clinic

Therapeutic Advances in Musculoskeletal Disease | December 18, 2025 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/1759720x251407060 | PMID 41427122 Get It

Background: Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare, disabling, genetic disorder characterized by progressive heterotopic ossification (HO). FOP care pathways are complex, and there are many underrepresented patients globally. Objectives: This scoping review aimed to identify global FOP case reports and investigate real-world management practices. Evidence sources, eligibility criteria, and charting methods: International/local databases and congress proceedings were searched. Publications reporting patient-level data for ⩾1 patient with an FOP primary diagnosis, published January 2000–January 2024, were eligible. Publication details, patient demographics, disease presentation, and care pathway were extracted. Data were charted through categorization of themes and frequency analyses. Results: Of 6064 publications screened, 369 were eligible, reporting on 541 patients with FOP. Most publications (82.4% (304/369)) reported an individual case; the remaining reported 2–25 cases. Cases were from 57 countries, most commonly in the Asia/Pacific region (47.0% (254/541)). Most patients had reportedly seen a single specialist (64.8% (59/91)), and care from multidisciplinary teams was reported for only 5.5% (5/91). HO (84.7% (458/541)) and great toe malformations (66.7% (361/541)) were the most commonly reported signs, though mobility limitations (46.2% (96/208)) and growths/lesions (38.5% (80/208)) were most common before diagnosis. The predominant drug classes reported for FOP treatment were corticosteroids (52.6% (102/194)) and nonsteroidal anti-inflammatory drugs (39.7% (77/194)). Surgeries were reported in 35.1% (190/541) of patients. Where specified, the most common surgery types were malformation correction/bone resection (43.6% (78/179)) and biopsies (34.1% (61/179)). Conclusion: This scoping review synthesized valuable real-world insights from case reports of FOP, potentially supporting outreach initiatives in underserved regions and facilitating shared learnings on diagnosis and treatment. Although the inherent selection bias of case studies toward atypical cases limits definitive conclusions, some global trends in the clinical management practices were revealed.